Reduce Divi's Laboratories: target of Rs 5,610: ICICI Securities

ICICI Securities recommended reduce rating on Divi's Laboratories with a target price of Rs 5,610 in its research report dated May 19, 2025.

Broker Research

May 21, 2025 / 15:39 IST

Reduce

26 Aug, 2025 12:21

Volume

Todays L/H

ICICI Securities's research report on Divi's Laboratories

Divi’s Laboratories’ (Divi’s) Q4FY25 outperformance was led by a strong uptick in its export (up 14.3%) markets such as US and Europe (+16% YoY) and better product mix; also, sharper overhead cost control fuelled 253bps of EBITDA margin expansion to 34.3%. Divi’s has started intermediate (including GLP-1) manufacturing for captive consumption at its Kakinada plant; over the next few months, it would vacate products from Unit 1&2 for GLP-1 products. Divi’s has established a niche in amino acids and solid/liquid phases of synthesis for GLP-1.

Outlook

We have increased our EPS for FY26E/FY27E by 3–7% to factor in better margins. We build in revenue/EBITDA/PAT CAGRs of 23.2%/30.8%/31.3% over FY25–27E. While we remain excited about the capex-driven growth and other margin-lucrative opportunities, the stock trades at pricey valuations of 58.8x FY26E, 44.9x FY27E earnings and EV/EBITDA multiple of 42x FY26E and 31.9x FY27E. We upgrade our rating to REDUCE, with a higher TP of INR 5,610 (earlier INR 4,500), based on 40x FY27E (45x FY26E previously) EPS of INR 140.

For all recommendations report, click here